Triptorelin
DRACPC ID DRACPC0001
Active Ingredients Triptorelin
Description A synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men.
Synonyms 6-D-Tryptophan-LH-RH; 6-D-Tryptophanluteinizing Hormone-releasing Factor; AY-25650; CL-118,532; Detryptoreline; Decapeptyl; Arvekap; (D-Trp6)-GnRH; Triptorelina; Triptorelinum; Trelstar; Triptodur; Triptorelin
Type Small Molecule
Disease Prostate cancer
Classification
GnRH agonist Peptide and derivative
Structure Information
Molecular Formula C64H82N18O13
Molecular Weight 1311.4
Active Sequence XHWSYwLRPG
Sequence Length 10
Modification X=Pyr, N-terminal NH2
IUPAC Name (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
InChI InChI=1S/C64H82N18O13/c1-34(2)23-46(56(88)75-45(13-7-21-69-64(66)67)63(95)82-22-8-14-52(82)62(94)72-31-53(65)85)76-58(90)48(25-36-28-70-42-11-5-3-9-40(36)42)78-57(89)47(24-35-15-17-39(84)18-16-35)77-61(93)51(32-83)81-59(91)49(26-37-29-71-43-12-6-4-10-41(37)43)79-60(92)50(27-38-30-68-33-73-38)80-55(87)44-19-20-54(86)74-44/h3-6,9-12,15-18,28-30,33-34,44-52,70-71,83-84H,7-8,13-14,19-27,31-32H2,1-2H3,(H2,65,85)(H,68,73)(H,72,94)(H,74,86)(H,75,88)(H,76,90)(H,77,93)(H,78,89)(H,79,92)(H,80,87)(H,81,91)(H4,66,67,69)/t44-,45-,46-,47-,48+,49-,50-,51-,52-/m0/s1
InChI_Key VXKHXGOKWPXYNA-PGBVPBMZSA-N
SMILES CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8
External Codes
PubChem CID 25074470
DrugBank Accession Number DB06825
NCI Thesaurus Code C1267
UNII 9081Y98W2V GSRS
CAS 57773-63-4
Drug approval
Drug indication
Triptorelin is indicated for the palliative treatment of advanced prostate cancer.
| Drug Name | Strength | Dosage Form/Route | Company | Marketing Status | Drug ID | Approval year |
|---|---|---|---|---|---|---|
| Trelstar | eq 3.75mg base/vial | Injectable; Intramuscular | Allergan Sales Llc | Prescription | NDA: 020715 | 2000 |
| Trelstar | eq 11.25mg base/vial | Injectable; Intramuscular | Allergan Sales Llc | Prescription | NDA: 021288 | 2001 |
| Trelstar | eq 22.5mg base/vial | Injectable; Intramuscular | Allergan Sales Llc | Prescription | NDA: 022437 | 2010 |
| Triptodur Kit | eq 22.5mg base/vial | For Suspension, Extended Release; Intramuscular | Arbor Pharms Llc | Prescription | NDA: 208956 | 2017 |
| Decapeptyl | 0.1 mg/ml | Solution; Subcutaneous | Ferring Inc | Prescription | DIN: 02389282 | 2012 |
| Trelstar | 3.75 mg/vial | Injectable; Intramuscular | Allergan Pharma Co. | Prescription | DIN: 02240000 | 2005 |
| Trelstar | 11.25 mg/vial | Injectable; Intramuscular | Allergan Pharma Co. | Prescription | DIN: 02243856 | 2005 |
| Trelstar | 22.5 mg/vial | Injectable; Intramuscular | Allergan Pharma Co. | Prescription | DIN: 02412322 | 2013 |
| ClinicalTrials.gov Identifier | Title | Condition or disease | Phase | Purpose |
|---|---|---|---|---|
| NCT01020448 | Prostate Cancer Antigen-3 (PCA-3) and TMPRSS2-ERG (T2-ERG) Score Changes During Initiation of Androgen Deprivation Therapy (ADT) With Triptorelin 22.5mg in Patients With Advanced Prostate Cancer (PCA): A Phase III, Single Arm Multicentre Study | Prostate Cancer | Phase 3 | Treatment |
| NCT01753297 | A Multicentric, Multinational (China and Russia), Randomised, Open, Controlled Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients | Prostate Cancer | Phase 4 | Treatment |
| NCT01969578 | A Randomized Phase II Study to Evaluate the Efficacy and Safety of Chemotherapy (CT) vs Androgen Deprivation Therapy (ADT) in Patients With Recurrent and/or Metastatic, Androgen Receptor (AR) Expressing, Salivary Gland Cancer (SGCs) | Salivary Gland Cancer | Phase 2 | Treatment |
| NCT00667069 | Randomized, Multicenter Study Comparing the Immediate Adjuvant Radiotherapy Associate With Hormonal Therapy of LH-RH Analogue (Decapeptyl® LP) vs Delayed Radiotherapy Until Biochemical Relapse Associated With Hormonal Therapy of LH-RH Analogue (Decapeptyl® LP) in Patients With Operable Prostate Cancer pT3 R1 pN0 or pNx at Intermediate Risk. | Prostate Cancer | Phase 3 | Treatment |
| NCT00412022 | Phase III Randomized Study of the Effects on Bone Mineral Density of Tamoxifen, Letrozole, and Letrozole + Zoledronic Acid as Adjuvant Treatment of Patients With Early Breast Cancer; VERSION 2 AMENDED Phase 3 Study of Triptorelin and Tamoxifen, Letrozole, or Letrozole + Zoledronic Acid in Adjuvant Treatment of Premenopausal Endocrine Responsive Breast Cancer Patients. | Breast Cancer | Phase 3 | Treatment |
More clinical information is obtained from ClinicalTrials.gov.
